Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F10 | P00742 | 6/20 | 0.52 |
| ▸ | SERPINC1 | P01008 | 3/20 | 0.49 |
| ▸ | FGF1 | P05230 | 4/20 | 0.44 |
| ▸ | BDNF | P23560 | 3/20 | 0.44 |
| ▸ | PTN | P21246 | 2/20 | 0.44 |
| ▸ | MDK | P21741 | 2/20 | 0.44 |
| ▸ | FGF2 | P09038 | 1/20 | 0.36 |
| ▸ | CXCL10 | P02778 | 1/20 | 0.36 |
| ▸ | CXCL8 | P10145 | 1/20 | 0.36 |
| ▸ | CCL2 | P13500 | 1/20 | 0.36 |
| ▸ | CCL5 | P13501 | 1/20 | 0.36 |
| ▸ | CXCL12 | P48061 | 1/20 | 0.36 |
| ▸ | F2 | P00734 | 1/20 | 0.35 |
| ▸ | HPSE | Q9Y251 | 3/20 | 0.34 |
| ▸ | PF4 | P02776 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27433034 | 0.88 | F10 (0.61) | F10SERPINC1FGF1BDNFPTN | |
| SCHEMBL27433042 | 0.86 | F10 (0.55) | F10SERPINC1FGF1BDNFPTN | |
| SCHEMBL14817755 | 0.81 | F10 (0.69) | F10SERPINC1FGF1BDNFPTN | |
| SCHEMBL15171284 | 0.81 | F10 (0.69) | F10SERPINC1FGF1BDNFPTN | |
| SCHEMBL19619414 | 0.81 | F10 (0.69) | F10SERPINC1FGF1BDNFPTN | |
| SCHEMBL17550968 | 0.80 | F10 (0.46) | F10SERPINC1FGF1BDNFPTN | |
| SCHEMBL16449895 | 0.79 | F10 (0.53) | F10SERPINC1FGF1BDNFPTN | |
| SCHEMBL19754845 | 0.79 | F10 (0.53) | F10SERPINC1FGF1BDNFPTN | |
| SCHEMBL12266894 | 0.79 | F10 (0.53) | F10SERPINC1FGF1BDNFPTN | |
| SCHEMBL12266890 | 0.79 | F10 (0.53) | F10SERPINC1FGF1BDNFPTN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160228572-A9 | Immobilised Biological Entities | CARMEDA AB (SE) | 2016-08-11 | — | — | US | disclosed |
| US-20130273122-A1 | Immobilised Biological Entities | CARMEDA AB (SE) | 2013-10-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130273122-A1 | Immobilised Biological Entities | FGB, SELE, EPCAM | F10 44/4885SERPINC1 4/4885FGF1 1194/4885 |
| US-20160228572-A9 | Immobilised Biological Entities | FGB, SELE, EPCAM | F10 44/4885SERPINC1 4/4885FGF1 1194/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.